Cannalysis , a testing company for cannabis, has raised $22 million in a new round of financing as it prepares to bring a new test for vaping additives to the market. The test, which the company is preparing to unveil later this week, will test for the presence and amount of Vitamin E acetate, a chemical compound that may be linked to the aping related illness that has swept through the U.S. in the past month. Cannalysis chief executive Brian Lannon said the new product was developed in response to the current crisis in the cannabis industry over illnesses related to vaping cannabis products. “The big story that’s been going out over the last week isn’t the product that’s going out in cannabis, but an additive called Vitamin E acetate. We have developed a test for that,” Lannon says. “ As part of the different compliance testing that’s required, it’s not mandated to test for any of these additives… What I’m anticipating based on the phone calls we’ve been getting is that a lot ...
Comments
Post a Comment